UNIROID-HC

Posology Adults Treatment with Uniroid-HC Ointment should be limited to seven days. Patients should be advised to return to their doctor if the condition persists beyond this time.

Directions for use and dosage schedule:

First wash the anal area gently with water and pat dry with cotton wool. With the finger, spread a small quantity of the ointment on the painful area without rubbing. Do not use toilet paper. Apply the ointment twice a day (morning and evening) and after each bowel movement, or as prescribed by the doctor.

The ointment can be used internally by means of the nozzle applicator which is supplied. Insert the nozzle applicator to full extent and squeeze the tube gently from the lower end whilst withdrawing. The nozzle applicator must be cleaned thoroughly in warm, soapy water before and after each use.

The ointment may be used separately or concurrently with the suppositories. Elderly Dosage modifications are not required in the elderly. Paediatric population Uniroid-HC Ointment is not recommended for use in children under 12 years of age unless directed by a doctor.

Method of administration For rectal use only

The frequencies of adverse events are ranked according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

4). When applied topically and to a large enough area, especially of damaged skin for long enough, or if under occlusive dressing, hydrocortisone may have this adverse effect. 4). 4). Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Apply only to the region of the rectum and anus and surrounding skin. Hydrocortisone can cause thinning and damage to the skin. Recurrent or prolonged application may increase the risk of contact sensitisation particularly to cinchocaine.

As with all preparations containing topical steroids, the possibility of systemic absorption should be considered. In particular, long-term continuous therapy should be avoided in infants. Adrenal suppression can occur even without occlusion.

Visual disturbance may be reported with systemic and topical corticosteroid use. If a patient presents with symptoms such as blurred vision or other visual disturbances, the patient should be considered for referral to an ophthalmologist for evaluation of possible causes which may include cataract, glaucoma or rare diseases such as central serous chorioretinopathy (CSCR).

Excipients This medicinal product contains cetostearyl alcohol. This may cause local skin reactions, such as contact dermatitis.

1. This product is contraindicated in tuberculosis, anal thrush and most viral lesions of the skin including herpes simplex, vaccinia and varicella.